Navigation Links
Sosei and Vectura Announce Start of Phase II Studies of QVA149 for the Treatment of COPD
Date:11/15/2007

long acting beta 2 agonist, as QVA149.

Under the terms of the agreement, Sosei and Vectura have already received $15 million each and will receive up to $172.5 million each for achieving pre-agreed clinical, regulatory and commercialisation targets for both the monotherapy and combination product. These potential milestones thus total up to $375 million. In addition, royalties on product sales will be paid for the monotherapy and the combination product. If a third combination product is developed by Novartis, using NVA237, further milestones and royalties may be payable.

About COPD

COPD is a chronic obstruction of the airways which in the developed world is caused primarily by smoking. Symptoms include chronic bronchitis and/or emphysema which slowly progress and eventually lead to a largely irreversible loss of lung function. COPD is currently the fourth most common cause of death and by 2020 is predicted to become the third most common cause of death and the fourth most important disability causing illness. The total financial burden of lung disease in Europe amounts to nearly EUR102 billion with COPD contributing almost one half of this figure. Around three-quarters of patients with advanced COPD are unable to perform normal everyday activities.

The current market for COPD drug therapy is estimated to be worth around $6 billion per annum and is forecast to grow to $11 billion by 2011 as a result of increasing diagnosis and treatment and the growth of high value new products.

About Sosei

Sosei is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. National Association of Subrogation Professionals (NASP), the Largest Insurance Subrogation Association in the World - Announced Today that Leslie Wiernik has Joined the Organization as Director of Education
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 2013 McGuff Pharmaceuticals, Inc. ... Drug Application (ANDA) for Hydroxyprogesterone Caproate Injection, USP 250mg/mL, ... Squibb’s drug fomerly known as Delalutin™. We are ... the anticipated approval and market introduction dates for McGuff’s ... status of our pending ANDA, to date, McGuff has ...
(Date:6/19/2013)... Calculating insurance rates is a complex process that ... and of course their own company policies. This process ... from company to company, and why by shopping around for ... often save, as car insurance can be a hefty expense ... the top factors that determine their car insurance premiums. ...
(Date:6/19/2013)... June 19, 2013 Sudden cardiac arrest can ... sets in an average of 5 minutes after cardiac arrest, ... 11 minutes. This means that death is highly probable if ... readily available for use. In response to this dire reality, ... to Save Lives Act (H.R. 2308) which would provide support ...
(Date:6/19/2013)... June 19, 2013 Anant Goel, CEO at ... changing rapidly. The first industrial revolution began in Britain in ... industry… when the factory was born. The second industrial revolution ... the moving assembly line and ushered in the age of ... the 21st century. Manufacturing is going digital and this could ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Indosoft ... Center ACD for Asterisk, announced today the ... 5.7. This enhancement offers improved options for extracting, ... dashboards for effective contact center management. , Large ... real-time captured as it happens from the call ...
Breaking Medicine News(10 mins):Health News:Current Progress Towards ANDA Approval of Hydroxyprogesterone Caproate Injection, USP 2Health News:icandrive.ca Provides Tips to Understand the Top Factors That Affect Car Insurance Premiums 2Health News:icandrive.ca Provides Tips to Understand the Top Factors That Affect Car Insurance Premiums 3Health News:AED.com Supports Automated External Defibrillator (AED) Legislation in Schools in US and UK 2Health News:RKNet Studios Announced Cognitions Bridge Intelligence Games for Fun, Cognitive Skills Testing and Development for Success in Life 2Health News:RKNet Studios Announced Cognitions Bridge Intelligence Games for Fun, Cognitive Skills Testing and Development for Success in Life 3Health News:RKNet Studios Announced Cognitions Bridge Intelligence Games for Fun, Cognitive Skills Testing and Development for Success in Life 4Health News:Indosoft Improves Q-Suite Real-time ACD Reporting to Enhance Contact Center Productivity 2
... 2011) Active children need to be watered with ... than a sports drink or water itself, say researchers ... summer weather, says Brian Timmons, research director of the ... principal investigator of the study. "Children become ...
... care costs arising from pressure ulcers, commonly known as ... in emergency departments, according to new research from the ... are at high risk for pressure ulcers in part ... researchers found that while the average cost of upgrading ...
... 17, 2011) Patients with clinically diagnosed superficial vein thrombosis (SVT), ... that commonly resolves on its own without treatment, are four ... a dangerous, often life-threatening condition, according to study results ... Journal of the American Society of Hematology (ASH). ...
... Reporter , WEDNESDAY, Aug. 17 (HealthDay News) -- Researchers ... useful in identifying women who have a higher risk ... This particular antibody, which was detected in blood, ... called mesothelin. This protein is present in advanced ovarian ...
... The Medical College of Wisconsin investigating latex allergy in ... health strategy to prevent allergic sensitization is by stopping ... studies pointed out this association of latex allergy to ... completely confirm this link in specific workers. Reducing the ...
... treating chronic wounds on patients in the United States. These ... than six million people who have them. The most common ... to venous disease (conditions related to or caused by veins ... but the quality of evidence showing which treatments work better ...
Cached Medicine News:Health News:Better mattresses improve care, cut hospital costs: U of T study 2Health News:Common vein condition increases risk for developing life-threating blood clots 2Health News:Blood Antibody May Signal Start of Ovarian Cancer 2Health News:Blood Antibody May Signal Start of Ovarian Cancer 3Health News:Using powder-free latex gloves reduces latex allergy rate in health care workers 2Health News:Johns Hopkins Evidence-based Practice Center awarded $475,000 project 2Health News:Johns Hopkins Evidence-based Practice Center awarded $475,000 project 3
(Date:6/19/2013)... , June 19, 2013 /PRNewswire-iReach/ -- Today leading ... all new data ranking Pharmaceutical web sites for usability, ... Sciences, User Experience Cloud platform, which compares how people ... on the web. The top three performers ... convert people overall. The bottom performers have usability problems, ...
(Date:6/19/2013)... 19, 2013 /PRNewswire-iReach/ -- In its first ... pharmaceutical company dedicated to advancing development of ... sustained release drug therapies in patient disease ... announced the acquisition of Enzon Pharmaceutical,s PEGylation ... associated product pipeline. Acquisition of this technology ...
(Date:6/19/2013)... 19, 2013  Omnicell, Inc. (NASDAQ: ... supply management solutions and analytics software for healthcare ... number one overall pharmacy equipment vendor in the ... a leading independent healthcare research firm, compared the ... its annual rankings. Omnicell also received the prestigious ...
Breaking Medicine Technology:Sunovion tops new Change Sciences User Experience Rankings for Pharmaceutical Industry while McNeil-PPC ranks worst overall 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 2Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 3Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 4
...   Unigene Laboratories, Inc. (OTCBB: UGNE), ... of peptide-based therapeutics, announced that Ashleigh Palmer, President and ... the Biotech Showcase™ 2012 in San Francisco, CA on ... p.m. ET).  Mr. Palmer,s presentation will include an overview of ...
... Md., Jan. 4, 2012 /PRNewswire-iReach/ -- ... pharmaceutical company focused exclusively in the HIV-1 therapeutic ... to provide medicinal chemistry services to support DFH ... maturation inhibitor drugs. Maturation inhibitors are a novel ...
Cached Medicine Technology:Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9 2DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs 2DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs 3
Fenestrated 14 mm blades. Wide extension of blade for protection of lids. Self-locking mechanism. Dull finish....
Solid 16 mm blades. Self-locking mechanism. Dull finish....
Infant model. Blades: 7 mm. Solid blades with locking mechanism. Dull finish....
Fenestrated 16 mm blades. Self-locking mechanism. Dull finish....
Medicine Products: